TWI915460B - 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途 - Google Patents

新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途

Info

Publication number
TWI915460B
TWI915460B TW110144518A TW110144518A TWI915460B TW I915460 B TWI915460 B TW I915460B TW 110144518 A TW110144518 A TW 110144518A TW 110144518 A TW110144518 A TW 110144518A TW I915460 B TWI915460 B TW I915460B
Authority
TW
Taiwan
Prior art keywords
methyl
compound
imidazol
indazole
piperidinyl
Prior art date
Application number
TW110144518A
Other languages
English (en)
Chinese (zh)
Other versions
TW202237611A (zh
Inventor
可西摩 多藍提
安尼克 喬葛勒
大衛 史蒂芬 赫溫
喬治 雅克
山德 奧瑞克 歐斯特
安東尼歐 瑞奇
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202237611A publication Critical patent/TW202237611A/zh
Application granted granted Critical
Publication of TWI915460B publication Critical patent/TWI915460B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW110144518A 2020-12-01 2021-11-30 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途 TWI915460B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
EP20210859.3 2020-12-01

Publications (2)

Publication Number Publication Date
TW202237611A TW202237611A (zh) 2022-10-01
TWI915460B true TWI915460B (zh) 2026-02-21

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110144518A TWI915460B (zh) 2020-12-01 2021-11-30 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途

Country Status (16)

Country Link
US (1) US20240002390A1 (enExample)
EP (1) EP4255908A1 (enExample)
JP (1) JP7840327B2 (enExample)
KR (1) KR20230116799A (enExample)
CN (1) CN116490182A (enExample)
AR (1) AR124170A1 (enExample)
AU (1) AU2021393722A1 (enExample)
CA (1) CA3197659A1 (enExample)
CL (1) CL2023001440A1 (enExample)
CO (1) CO2023006912A2 (enExample)
CR (1) CR20230218A (enExample)
IL (1) IL303064A (enExample)
MX (1) MX2023006176A (enExample)
PE (1) PE20240099A1 (enExample)
TW (1) TWI915460B (enExample)
WO (1) WO2022117477A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (en) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Egfr inhibitors for the treatment of cancer
WO2022117475A1 (en) 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives
US20260007678A1 (en) * 2022-05-13 2026-01-08 Hoffmann-La Roche Inc. Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115218A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
WO2020002487A1 (en) 2018-06-29 2020-01-02 F. Hoffmann-La Roche Ag Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987914C (en) 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
AR113299A1 (es) 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
AR121167A1 (es) 2019-06-21 2022-04-27 Hoffmann La Roche DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115218A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
WO2020002487A1 (en) 2018-06-29 2020-01-02 F. Hoffmann-La Roche Ag Compounds

Also Published As

Publication number Publication date
US20240002390A1 (en) 2024-01-04
MX2023006176A (es) 2023-06-08
AU2021393722A1 (en) 2023-04-13
CR20230218A (es) 2023-07-07
CO2023006912A2 (es) 2023-06-09
IL303064A (en) 2023-07-01
CL2023001440A1 (es) 2023-12-01
CA3197659A1 (en) 2022-06-09
WO2022117477A1 (en) 2022-06-09
JP7840327B2 (ja) 2026-04-03
EP4255908A1 (en) 2023-10-11
TW202237611A (zh) 2022-10-01
AR124170A1 (es) 2023-02-22
JP2023550902A (ja) 2023-12-06
KR20230116799A (ko) 2023-08-04
PE20240099A1 (es) 2024-01-18
CN116490182A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
EP3986898B1 (en) Egfr inhibitors for the treatment of cancer
TWI833773B (zh) 化合物
TW202115073A (zh) 新穎的egfr抑制劑
EP3677583A1 (en) Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
CN110325528A (zh) 2-苯并吡嗪基-n-杂芳基-2-苯基-乙酰胺化合物
JP7840324B2 (ja) 新規インダゾール誘導体
JP7840327B2 (ja) 新規インダゾールアセチレン誘導体
TW202136263A (zh) 新穎 egfr 抑制劑
JP7798887B2 (ja) 新規インダゾール誘導体
TW202136264A (zh) 新穎ｅｇｆｒ抑制劑
TW202402276A (zh) 新穎吲唑衍生物
RU2853003C1 (ru) Новые индазолацетиленовые производные
WO2022155111A1 (en) Indole derivatives as kinase inhibitors
HK40094041A (zh) 新的吲唑乙炔衍生物
HK40092553A (zh) 新的吲唑衍生物
HK40115444A (zh) 新的吲唑衍生物
HK40077526B (zh) 对核受体具有活性的化合物
HK40067225B (zh) 用於治疗癌症的egfr抑制剂
HK40067225A (zh) 用於治疗癌症的egfr抑制剂
HK40067220A (zh) 新egfr抑制剂
HK40067226A (zh) 用於癌症治疗的egfr抑制剂
HK40067226B (zh) 用於癌症治疗的egfr抑制剂